Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose by Santos, K. B. dos et al.
LETTER TO THE EDITOR
Lomustine use in combination with etoposide, cytarabine and
melphalan in a brief conditioning regimen for auto-HSCT
in patients with lymphoma: the optimal dose
Bone Marrow Transplantation (2014) 49, 1239–1240; doi:10.1038/
bmt.2014.121; published online 2 June 2014
Autologous hematopoietic SCT (auto-HSCT) is widely employed as
consolidation therapy in aggressive Non-Hodgkin lymphoma
(NHL) and relapsed or refractory classic Hodgkin's lymphoma.
However, there is no evidence regarding the best conditioning
regimen to be used. New schemes have therefore been proposed
to reduce the toxicity, costs related to the procedure and
hospitalization time, without compromising the quality of life
and survival of patients.1 The maximum recommended dose of
lomustine (CCNU) associated with etoposide and cyclophospha-
mide has been 600 mg/m2.2,3 However, when it is associated with
a combination of etoposide, ara-C and cyclophosphamide, or
etoposide, ara-C and melphalan, a dose of 200mg/m2 has been
used.4–6
Although the success of auto-HSCT depends on several
variables, the lower the toxicity and the duration of neutropenia
the smaller the treatment-related mortality.
Given that lomustine has low pulmonary toxicity, is easy to
administer, and does not yet have a deﬁned maximum tolerated
dose (MTD) when used in combination with melphalan, ara-C and
etoposide for conditioning regimens in auto-HSCT in patients
with lymphoma, we proposed to carry out a phase 1 study with
dose escalation of lomustine.2 The study was approved by the
local ethics committee under the number 139-420-2011, CAAE
0102.0.420.000-11.
To determine the MTD of lomustine we realized a prospective
study with a traditional 3:3 dose scaling, with three cohorts
involving three patients. If a patient presented dose-limiting
toxicity (DLT), three more patients were included in the same
cohort. If two patients exhibited DLT, then the dosage used by
that cohort of patients was considered as exceeding MTD and
another intermediate dose to the one previously used was tested.
The absence of medullary grafting or platelets after 30 days of
infusion of HSC, or the presence of grade 4 non-hematologic
toxicity, or grade 3 non-hematologic toxicity, such as a fever,
infection, skin rash, fatigue, mucositis, electrolyte imbalance,
dehydration, pain, glucose intolerance, pulmonary toxicity,
acute toxicity related to treatment or death by any cause, was
deﬁned as DLT.
The initial cohort received lomustine (Citostal) at a dose of
200mg/m2 (L200), and the subsequent cohort at a dose of
400mg/m2 (L400). Because L400 exceeded the MTD, a third
cohort with lomustine at a dose of 300 mg/m2 (L300) was
analyzed. The lomustine was administered on day 4 of condition-
ing, the other drugs were administered in the following days and
doses: etoposide 1000mg/m2 (day 3), cytarabine 4000mg/m2
(day 2) and melphalan 140mg/m2 (day 1). The infusion of HSC was
administered on day 0 (zero) 24 h after the end of melphalan.
We evaluated 14 patients with a mean age of 36 years (16–58).
Six patients had PR and eight were in CR at the time of auto-HSCT.
The characteristics of the patients are described in Table 1.
Six patients participated in the cohort L200, and since one out
of six (16.5%) presented DLT (death by sepsis), three more patients
had to be included in this cohort. In the cohort L400, two out of
the two (100%) patients presented DLT (grade 4 gastrointestinal
toxicity and sinusoidal obstruction syndrome). Given that
400mg/m2 of lomustine proved to exceed the MTD, another
cohort with lomustine at a dose of 300 mg/m2 (L300) was
evaluated. From the three patients initially analyzed, one out of
three (33.3%) presented reversible grade 4 neurological toxicity,
which meant that three more patients had to be included in this
cohort. In the end, the dose of 300 mg/m2 was determined to be
the the MTD of lomustine. The main toxicities observed in patients
according to the WHO (World Health Organization) criteria are
described in Table 2.
The patients received an average of 6.91 × 106 (1.37 to
18.8 × 106) CD34+ cells per kg. The average length of hospitaliza-
tion was 22 days (15–70) and the mean duration of neutropenia
(neutrophil count o500/mm3) was 7.8 days (6–18), which was
below our historical control of 13 days observed with the CBV
protocol (cyclophosphamide, 1.2 g/m2/day on day -6, -5, -4 and -3;
Carmustine, 300 mg/m2 on day -6; Etoposide, 200mg/m2/day,
12/12 h on day -6, -5 and -4).7
The grafting of neutrophils and platelets occurred on day +10
and day +12 after auto-HSCT, respectively. Interestingly, we
observed a signiﬁcant reduction in the need for hemocomponents
compared with our historical series. Only 6/14 (42.8%) patients
needed RBC transfusion and 4/14 (28.5%) patients did not require
any transfusion support.
Table 1. Characterization of patients
Characteristics N %
Gender
Male 8 57.1
Female 6 42.9
Hodgkin lymphoma
Nodular sclerosis 7 50
Mixed cellularity 1 7.1
Non-Hodgkin Lymphoma
Diffuse large B-cell lymphoma 3 21.4
Follicular lymphoma 1 7.1
Mantle cell lymphoma 1 7.1
T-cell lymphoma, NOS 1 7.1
Bulky
Yes 8 57.1
No 6 42.9
Status
Partial remission 6 42.9
Complete remission 8 57.1
Abbreviation: NOS= not otherwise speciﬁed.
Bone Marrow Transplantation (2014) 49, 1239–1240
© 2014 Macmillan Publishers Limited All rights reserved 0268-3369/14
www.nature.com/bmt
Our results conﬁrm recent study data, which found low toxicity
and a medullary grafting time similar to ours using lomustine at a
dose of 200 mg/m2, also associated with ara-c, etoposide and
melphalan.5 In the same way, higher doses of lomustine have
been used in other chemotherapy schemes because of its lower
pulmonary toxicity when compared with carmustine. Pulmonary
toxicity usually occurs with lomustine when doses higher than
1000mg/m2 are used.2,3
In our study we were therefore able to develop a new protocol
using conventional doses of lomustine, which allowed us to
reduce the hospitalization time and the days of conditioning, but
without reducing the number of drugs recommended or the
planned total dose. In addition, we reduced the period of
neutropenia and the hospitalization time compared with the
conditioning protocol previously used in our institution.
At the same time, we evaluated the MTD of lomustine in
association with ara-c, etoposide and melphalan. We observed
1/14 (7.2%) deaths from pneumonia during the hospitalization
and 3/14 (21.4%) patients presented grade 4 toxicity, one with a
dose of 300mg/m2 and two with 400mg/m2. We therefore
established the MTD to be 300 mg/m2 for lomustine combined
with high doses of etoposide, Ara-C and melphalan in condition-
ing of auto-HSCT in patients with lymphoma.
In conclusion, the LEAM protocol (lomustine, 300mg/m2 on day
4; etoposide, 1000mg/m2 on day 3; cytarabine, 4000mg/m2 on
day 2 and melphalan, 140mg/m2 on day 1), proved to be a
feasible conditioning regimen that could be administered rapidly,
associated with a short period of neutropenia and acceptable
toxicity. We are currently conducting a phase 2 study with a dose
of 300mg/m2 of lomustine.
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Table 2. Toxicities of the analyzed patients
Toxicity N %
Temporary alopecia
Grade I 0 0
Grade II 2 14.3
Grade III 12 85.7
Grade IV 0
Mucositis
Grade I 2 14.2
Grade II 1 7.1
Grade III 1 7.1
Grade IV 0 0
Gastro-intestinal toxicity
Grade I 4 28.5
Grade II 2 14.2
Grade III 3 21.4
Grade IV 0
Cutaneous toxicity
Grade I 1 7.1
Grade II 0 0
Grade III 0 0
Grade IV 0 0
Renal toxicity
Grade I 1 7.1
Grade II 0 0
Grade III 0 0
Grade IV 0 0
Neurological toxicity
Grade I 1 7.1
Grade II 0 0
Grade III 0 0
Grade IV 0 0
Sinusoidal obstruction syndrome 2 14.2
Infection 7 50
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